Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016

Abstract

Background and study aims Pancreatic cancer (PC) is the fourth most common cause of cancer death in the United States. Previous studies have suggested a survival benefit for endoscopic ultrasound (EUS), an important tool for diagnosis and staging of PC. This study aims to describe EUS use over time and identify factors associated with EUS use and its impact on survival.

Patients and methods This was a retrospective review of the Surveillance, Epidemiology and End Results (SEER) database linked with Medicare claims. EUS use, clinical and demographic characteristics were evaluated. Chi-squared analysis, Cochran-Armitage test for trend, and logistic regression were used to identify associations between sociodemographic and clinical factors and EUS. Kaplan-Meier and Cox proportional hazard ratios were used for survival analysis.

Results EUS use rose during the time period, from 7.4 % of patients in 2000 to 32.4 % in 2015. Patient diversity increased, with a rising share of older, non-White patients with higher Charlson comorbidity scores. Both clinical (receipt of other therapies, PC stage) and nonclinical factors (region of country, year of diagnosis) were associated with receipt of EUS. While EUS was associated with a survival improvement early in the study period, this effect did not persist for PC patients diagnosed in 2012 to 2015 (median survival 3 month ± standard deviation [SD] 9.8 months without vs. 4 months ± SD 8 months with EUS).

Conclusions Our data support previous studies, which suggest a survival benefit for EUS when it was infrequently used, but finds that benefit was attenuated as EUS became more widely available.

Publication History

Received: 11 May 2021

Accepted: 10 August 2021

Article published online:
14 January 2022

• References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Can J Clin 2020; 70: 7-30
• 2 Eloubeidi MA. et al. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc 2016; 83: 17-28
• 3 Tempero MA. et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. . J Natl Compr Canc Netw 2012; 10: 703-713
• 4 Ngamruengphong S. et al. EUS and survival in patients with pancreatic cancer: a population-based study. Gastrointest Endosc 2010; 72: 78-83, 83.e1–2
• 5 Rustgi SD. et al. Age, socioeconomic features, and clinical factors predict receipt of endoscopic retrograde cholangiopancreatography in pancreatic cancer. World J Gastrointest Endosc 2019; 11: 133-144
• 6 Shapiro M. et al. Associations of socioeconomic variables with resection, stage, and survival in patients with early-stage pancreatic cancer. JAMA Surg 2016; 151: 338-345
• 7 Zeng C. et al. Disparities by Race, Age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990 to 2010. JAMA Oncol 2015; 1: 88-96
• 8 Schmocker RK. et al. Utilization of preoperative endoscopic ultrasound for pancreatic adenocarcinoma. HPB 2017; 19: 465-472
• 9 Adler DG. et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc 2005; 62: 1-8
• 10 National Cancer Institute. Overview of the SEER Program. June 23, 2017. http://seer.cancer.gov/about/overview.html
• 11 Amin S. et al. Metformin Improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol 2016; 111: 1350-1357
• 12 Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 2006; 44: 921-928
• 13 Charlson ME. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
• 14 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619
• 15 Klabunde CN. et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267
• 16 Ruhl JL, Hurlbut CC, Ries LAG. et al. Summary Stage 2018: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2018
• 17 Young JL Jr, Roffers SD, Ries LAG. et al. SEER Summary Staging Manual – 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001 NIH Pub. No. 01-4969
• 18 Saleh MMA. et al. Preoperative endoscopic stent placement before pancreaticoduodenectomy: A meta-analysis of the effect on morbidity and mortality. Gastrointest Endosc 2002; 56: 529-534
• 19 Parmar AD. et al. Evaluating comparative effectiveness with observational data: endoscopic ultrasound and survival in pancreatic cancer. Cancer 2013; 119: 3861-3869
• 20 de Geus SW. et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery 2017; 161: 592-601
• 21 Evans DB. et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502
• 22 Itchins M. et al. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. Eur J Surg Oncol 2017; 43: 1711-1717
• 23 Shrestha B. et al. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Med 2017; 6: 1552-1562
• 24 Zhan HX, Xu JW, Wu D. et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med 2017; 16: 1201-1219
• 25 Cooper GS. et al. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002; 40 IV-43-8
• 26 Cooper GS. et al. The utility of Medicare claims data for measuring cancer stage. Med Care 1999; 37: 706-711
• 27 National Cancer Institute. Measures that are limited or not available in the data. April 30, 2021. https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html